373 related articles for article (PubMed ID: 30357021)
1. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer.
O'Rourke JM; Sagar VM; Shah T; Shetty S
World J Gastroenterol; 2018 Oct; 24(39):4436-4447. PubMed ID: 30357021
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.
Keenan BP; Fong L; Kelley RK
J Immunother Cancer; 2019 Oct; 7(1):267. PubMed ID: 31627733
[TBL] [Abstract][Full Text] [Related]
3. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
4. Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma.
Xia Y; Brown ZJ; Huang H; Tsung A
Cancer Med; 2021 Sep; 10(18):6374-6383. PubMed ID: 34390203
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
6. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
Zhang Q; Lou Y; Bai XL; Liang TB
World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
[TBL] [Abstract][Full Text] [Related]
7. Tristetraprolin Promotes Hepatic Inflammation and Tumor Initiation but Restrains Cancer Progression to Malignancy.
Dolicka D; Sobolewski C; Gjorgjieva M; Correia de Sousa M; Berthou F; De Vito C; Colin DJ; Bejuy O; Fournier M; Maeder C; Blackshear PJ; Rubbia-Brandt L; Foti M
Cell Mol Gastroenterol Hepatol; 2021; 11(2):597-621. PubMed ID: 32987153
[TBL] [Abstract][Full Text] [Related]
8. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives.
Roth GS; Decaens T
Eur J Cancer; 2017 Dec; 87():101-112. PubMed ID: 29145036
[TBL] [Abstract][Full Text] [Related]
9. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J
Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711
[TBL] [Abstract][Full Text] [Related]
10. Implication of the Hedgehog pathway in hepatocellular carcinoma.
Della Corte CM; Viscardi G; Papaccio F; Esposito G; Martini G; Ciardiello D; Martinelli E; Ciardiello F; Morgillo F
World J Gastroenterol; 2017 Jun; 23(24):4330-4340. PubMed ID: 28706416
[TBL] [Abstract][Full Text] [Related]
11. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.
Mukaida N; Nakamoto Y
World J Gastroenterol; 2018 May; 24(17):1839-1858. PubMed ID: 29740200
[TBL] [Abstract][Full Text] [Related]
12. Autophagy in the "inflammation-carcinogenesis" pathway of liver and HCC immunotherapy.
Yu S; Wang Y; Jing L; Claret FX; Li Q; Tian T; Liang X; Ruan Z; Jiang L; Yao Y; Nan K; Lv Y; Guo H
Cancer Lett; 2017 Dec; 411():82-89. PubMed ID: 28987386
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of Hepatocellular Carcinoma.
Heinrich B; Czauderna C; Marquardt JU
Oncol Res Treat; 2018; 41(5):292-297. PubMed ID: 29705790
[TBL] [Abstract][Full Text] [Related]
14. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
[TBL] [Abstract][Full Text] [Related]
15. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
16. Intrahepatic metastases may be specific to hepatocellular carcinoma due to the coagulation and fibrinolytic systems (Review).
Li X; Gu B; Wang B; Feng Z; Ma Y; Li H; Lucas A; Chen H
Oncol Rep; 2020 Dec; 44(6):2345-2352. PubMed ID: 33125140
[TBL] [Abstract][Full Text] [Related]
17. Annexin A2 promotion of hepatocellular carcinoma tumorigenesis
Qiu LW; Liu YF; Cao XQ; Wang Y; Cui XH; Ye X; Huang SW; Xie HJ; Zhang HJ
World J Gastroenterol; 2020 May; 26(18):2126-2137. PubMed ID: 32476780
[TBL] [Abstract][Full Text] [Related]
18. Recent progress in the emerging role of exosome in hepatocellular carcinoma.
Abudoureyimu M; Zhou H; Zhi Y; Wang T; Feng B; Wang R; Chu X
Cell Prolif; 2019 Mar; 52(2):e12541. PubMed ID: 30397975
[TBL] [Abstract][Full Text] [Related]
19. B lymphocytes limit senescence-driven fibrosis resolution and favor hepatocarcinogenesis in mouse liver injury.
Faggioli F; Palagano E; Di Tommaso L; Donadon M; Marrella V; Recordati C; Mantero S; Villa A; Vezzoni P; Cassani B
Hepatology; 2018 May; 67(5):1970-1985. PubMed ID: 29105104
[TBL] [Abstract][Full Text] [Related]
20. Treatment of inoperable hepatocellular carcinoma with immunotherapy.
Tighe SP; Iqbal U; Fernandes CT; Ahmed A
BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31352386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
